Introduction
Currently, prostate cancer is one of the most common newly diagnosed malignancies in men worldwide [1] . Before the disease becomes castration resistant, androgen-deprivation therapy (ADT) is the standard therapy for metastatic prostate cancer. However, after about 18-24 months of response [2] , most patients develop castration-resistant prostate cancer (CRPC). Once it becomes metastatic CRPC (mCRPC), which is a heterogeneous disease with enormous variability of prognosis and treatment response between patients, how to predict treatment response and prognosticate in these patients poses a major challenge.
Despite becoming castration resistance, the androgen receptor (AR) of these prostate cancer cells are thought to still be active [3, 4] , and for this reason several new strategies to inhibit AR signalling pathways have recently been developed, including abiraterone acetate (AA). AA inhibits CYP-17 lyase and hydroxylase, enzymes essential for androgen production, which results in undetectable serum testosterone concentrations [5] [6] [7] . AA plus prednisone has been shown to improve overall survival (OS) in chemotherapy pretreated or chemotherapy-na€ ıve patients with mCRPC [8] [9] [10] [11] . However, there is heterogeneity in survival benefits obtained from AA in different patients and about one-third of patients even exhibit primary resistance without showing any decline in PSA levels [12] . In addition, with the application of novel therapeutic options, the absence of reliable and easily available biomarkers to predict treatment response means that prognosis is a major challenge in mCRPC treatment.
It has been hypothesised that neuroendocrine differentiation (NED) is promoted by selective pressure under AR-targeted therapies and displays a mechanism of adaptive treatment resistance [13] . NED has been identified in 43-85% of cases with CRPC, which express NED markers such as chromogranin A (CgA) and neurone-specific enolase (NSE) [14] [15] [16] [17] [18] . In addition, elevation of NED markers in serum has shown to be consistent with the rate of NED detected in tumour tissue [19] . Moreover, NED markers are released not only by the primary tumour, but also by metastases, confirming that circulating NED markers could be more reliable parameters for assessing the NED status of mCRPC. Owing to this, serum CgA and NSE levels may be reliable and convenient markers to reflect NED in mCRPC.
In accordance with previous research, NED, which results in the loss of ARs, correlates with tumour aggressiveness and poor prognosis [20] . Baseline CgA and NSE levels have also been shown to be significant prognostic factors in mCRPC in the post-chemotherapy setting in patients treated with AA and enzalutamide [16, 17, 21] . Furthermore, reports suggest that NED progression can occur at any stage, which is driven by ADT [22, 23] , and expression analysis of mCRPC tissue obtained after resistance to AA and enzalutamide has shown NED (pure and mixed) to be present in 39% of cases [24] . So we hypothesised that patients with a more prominent NED status before AA treatment or who experience NED progression during AA treatment may have a much worse prognosis. To date, the prognostic utility of variations in serum CgA and NSE levels in patients with mCRPC treated with AA has not been evaluated.
We, therefore, retrospectively assessed the expression levels of serum CgA and NSE in 40 patients with mCRPC before and after 3 months of AA treatment. Our aim was to evaluate the prognostic utility of the variation of CgA and NSE in the first 3 months of AA treatment and baseline CgA and NSE levels in mCRPC. We determined their impact on OS, radiographic progression-free survival (rPFS) and PSA progression-free survival (PSA-PFS).
Patients and Methods
Men aged ≥18 years with mCRPC were eligible and included those with: histologically confirmed adenocarcinoma of the prostate; ongoing ADT with a serum testosterone level of <50 ng/dL (1.7 nmol/L); previous anti-androgen therapy followed by documented PSA progression after discontinuing the anti-androgen, and disease progression according to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria. After obtaining the approval from the Committee for Ethics of Renji Hospital and informed consent from the patients, 40 chemotherapy pretreated or chemotherapy-na€ ıve patients were scheduled for systemic treatment with AA. Patients were treated at the Department of Urology, Renji Hospital between 2013 and 2016. The serum levels of CgA and NSE were measured in these patients at baseline and after 3 months of AA treatment.
The study endpoints were PSA-PFS, rPFS and OS. PSA-PFS was determined according to the PCWG2 criteria [25] , and radiographic progression was based on Response Evaluation Criteria in Solid Tumors (RECIST) [25] or two or more new bone lesions on bone scan or death, whichever occurred first.
Samples were obtained from Renji Hospital Biobank, Shanghai Jiaotong University School of medicine, and all the donors signed the informed consent. All serum and plasma samples were immediately frozen and stored at -20°C until analysis. Total PSA was measured using a chemoluminescence immunoassay (Beckman Coulter, USA). For quantitative determination of CgA (normal range <100 ng/mL) the ELISA method was used (LDN, Germany) and for NSE (normal range <18 ng/mL) determination, electrochemiluminescence immunoassay (Roche Diagnostics GmbH, Germany) was used.
For statistical analyses, frequencies and proportions were calculated for categorical variables, while means, medians, and ranges were computed for continuous variables. Association analyses between CgA, NSE and PSA were performed with Pearson's correlation. Correlations with PSA-PFS, and rPFS, and OS were assessed using Kaplan-Meier curves with log-rank statistics. Furthermore, uni-and multivariate Cox regression analyses were used to calculate their respective hazard ratios (HRs) and 95% CIs. Only factors significant in univariate analyses were included in the subsequent multivariate analyses. A test result was considered as statistically significant for a P < 0.05. We used the Statistical Package for the Social Sciences (SPSS â version 19.0) for all key analyses.
Results
In all, 40 patients with mCRPC met the eligibility criteria between 2013 and 2016. The clinical and pathological data of all patients are listed in Table 1 . In all, 18 (45%) patients had received chemotherapy before AA treatment, while the others were chemotherapy na€ ıve. 
NED markers and PSA levels
The median (IQR) serum CgA, NSE and PSA levels at baseline were: 93.3 (75.9-177.2) ng/mL, 16.1 (12.9-18.8) ng/mL and 40.8(17.4-91.5) ng/mL, respectively.
Serum CgA and NSE levels at baseline were above the upper limit of normal in 18 (45%) and 10 (25%) patients, respectively, and 19 patients had either elevated CgA or NSE levels. Neither, CgA and NSE levels showed a correlation (Pearson's r = 0.17, P = 0.296), nor were PSA levels correlated with these NED serum markers (PSA and NSE Pearson's r = 0.13, P = 0.43; PSA and CgA Pearson's r = 0.19, P = 0.25). After 3 months of AA treatment, 21 (52.5%) and 16 (40%) patients had serum CgA and NSE levels increases, and 23 patients with either serum CgA or NSE levels increases compared with the baseline.
According to baseline CgA and NSE serum levels, we divided all patients in our study into two groups: Group A, without the elevation of NED markers before AA treatment; and Group B, with the elevation of at least one NED marker before AA treatment. In accordance with CgA and NSE variations during the first 3 months of AA treatment, we divided all patients in our study into two groups: Group C, without any NED marker increase in the first 3 months of AA treatment; and Group D, with at least one NED marker increase in the first 3 months of AA treatment.
Association of NED markers with OS
In the Kaplan-Meier analysis, the median OS was 30.1 months (95% CI 29. Table 2) .
Association of NED markers with PSA-PFS
In the Kaplan-Meier analysis, the median PSA-PFS was 13.4 months (95% CI 12.0-14.8) in the Group A and in the Group B was 9.2 months (95% CI 7.3-11.1) (P < 0.001; Fig. 1 ). The median PSA-PFS was 13.4 months (95% CI 12.0-14.8) in the Group C and in the Group D was 9.2 months (95% CI 7.3-11.1) (P < 0.001; Fig. 2 ). In a multivariate Cox regression analysis, together with LDH, elevation of at least one of the NED markers (≥1 marker positive vs both markers negative) and CgA and NSE Table 3) .
Association of NED markers with rPFS
In the Kaplan-Meier analysis, the median rPFS was 14.5 months (95% CI 12.7-16.3) in the Group A and in the Group B was 10.4 months (95% CI 9.8-11.0) (P < 0.001; Fig. 1 ). The median rPFS was 15.1 months (95% CI 13.4-16.8) in the Group C in the first 3 months of AA treatment and in Group D was 10.2 months (95% CI 9.4-11.0) (P < 0.001; Fig. 2 ). In multivariate Cox regression analysis, together with LDH, elevation of at least one of the NED markers (≥1 marker positive vs both markers negative) and CgA and NSE increase during the first 3 months of AA treatment (≥1 marker positive vs both markers negative) independently predicted rPFS (HR 1.02, 95% CI 1.00-1.04, P = 0.041; HR 12.89, 95% CI 1.44-24.99, P = 0.014) ( Table 4) .
Discussion
With the application of novel AR-targeted therapies in mCRPC, great importance has been attached to the prognostic and therapeutic implications of NED. NED, which is caused by selective pressure under AR-targeted therapies, displays a mechanism of adaptive treatment resistance [13] . NED cells in the prostate are not regulated by androgens and are resistant to hormonal therapies. CgA and NSE levels in serum have shown to be consistent with the rate of NED detected in tumour tissue [19] . In addition, elevated serum CgA and NSE levels are associated with NED of prostate cancer and resistance to ADT, which represent poor prognostic factors for prostate cancer [16, 17, 21, 26, 27] . AA exerts its therapeutic actions on mCRPC by resulting in undetectable serum testosterone concentrations. Owing to this, its therapeutic effect might be influenced by NED as well. So we postulated that in patients with mCRPC associated with high baseline serum CgA and NSE levels or who experience CgA and NSE increases during AA treatment may show resistance to treatment with AA and thus have a poor prognosis. Prior investigations suggest that NED progression can occur at any stage and is driven by ADT [22, 23] . Furthermore, experimental research has shown the NED prostate cancer could contribute to resistance to even novel hormonal therapies [13] and expression analysis of mCRPC tissue obtained after resistance to AA and enzalutamide has also shown NED (pure and mixed) in 39% of cases [24] . AA, a novel AR-targeted therapy, has also been found to drive NED, which has been described in case reports [28, 29] . In contrast to previous studies, von Hardenberg et al. [15] conducted an analysis of 35 chemotherapy-na€ ıve patients with CRPC treated with chemotherapy, of which 16 were treated with AA. Serum CgA, NSE and pro-gastrin-releasing peptide were evaluated before chemotherapy. In univariable analyses to test the influence of AA treatment and its duration of treatment on circulating NED markers, they found AA treatment and its duration were not associated with higher circulating NED marker levels, so they concluded that patients with CRPC after first-line treatment with AA are not at a higher risk of developing NED. However, we thought that it could also be interpreted as heterogeneity in the influence of AA on NED in CRPC. In the present study, we found after 3 months of AA treatment, either serum CgA or NSE levels increases compared with baseline occurred in 23 patients, while in the remaining 17 patients there was no NED marker increase. Moreover, patients with elevated serum CgA or NSE levels before AA treatment or who had CgA or NSE levels increases during AA treatment may have a much worse prognosis. It might mean that the patients with NED progression during AA treatment or with more prominent NED status would have worse survival outcomes and the serial evaluation of serum CgA and NSE levels would help in distinguishing the patients with mCRPC who would achieve a better survival benefit from AA treatment.
In our present study, there was no correlation between CgA and NSE serum concentrations and these results are consistent with previous studies [27, 30] . Therefore, we combined either baseline serum CgA and NSE levels or their variations during the first 3 months of AA treatment to account for heterogeneous marker secretion in serum and stratified patients in to two groups according to either baseline serum CgA and NSE levels elevation or those who had increases in these markers during the first 3 months of AA treatment (Groups A and B or Groups C and D).
Our present results are supported by previous reports. In mCRPC treated with AA or enzalutamide, higher serum CgA and NSE levels at baseline were significantly related to worse prognosis [16, 17, 21] . Heck et al. [17] retrospectively measured CgA and NSE levels in serum samples of 45 patients with mCRPC before AA treatment in a postchemotherapy setting. They found a correlation between [21] reported that in a multivariate analysis there was a correlation between elevated CgA and shorter OS, and a strong trend towards shorter clinical PFS. We hypothesised that because of a lack of ARs, the progressing NED component of mCRPC would lead to resistance to novel AR-targeted therapies and may therefore influence overall clinical outcome of mCRPC treated with novel AR-targeted therapies.
However, as we know, to date there has been no evaluation of the prognostic utility of the variation of serum CgA and NSE levels in mCRPC treated with AA. Additionally, previous published studies [16, 17, 21] have investigated the prognostic effects of baseline CgA and NSE levels in mCRPC treated with AA only in the post-chemotherapy setting.
Since 2004 docetaxel, cabazitaxel, AA, enzalutamide, sipuleucel-T, and radium-223 have been approved for the clinical treatment of CRPC. At present, the optimal personalised sequence of these agents to achieve the maximal clinical benefit still needs to be clarified. Cabrespine et al. [31] reported a better chemotherapy response in patients with CRPC with increased serum CgA and CgA variations during chemotherapy. Moreover, they claimed that given the decrease in serum CgA in patients with a chemotherapy response, chemotherapy might be able to reverse the process toward non-NE cells. We postulated that as NED is a major pathway that leads to CRPC proliferation, higher chemotherapy antitumor activity might be expected in tumours with a higher NE component and, thus, increased serum CgA. However, it is interesting to note in our present study that increased serum NED markers and variations in these predicted much worse prognostic outcomes in mCRPC treated with AA. Therefore, chemotherapy rather than AA might be a better choice for mCRPC with elevated baseline serum CgA or NSE levels or in those who experience CgA or NSE increases during AA treatment. To determine this, we would conduct a randomised case-control study to investigate the best treatment choice in mCRPC based on CgA and NSE serum levels.
There are some limitations to our present study. Firstly, it was based on retrospective data. Secondly, the patient data were collected from a single institution with a relatively small sample size. Our present results need to be validated by prospective research and patient data from multiple centres.
Conclusion
In our present study, we found that CgA and NSE elevation during the first 3 months of AA treatment and elevated baseline CgA and NSE levels significantly predicted poorer OS, rPFS and PSA-PFS in mCRPC treated with AA. It is suggested that serial CgA and NSE evaluation would help clinicians in distinguishing which patients with mCRPC would achieve the best survival benefit from AA treatment.
